Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGX942 for Oral Mucositis in Head and Neck Cancer
NCT03237325Phase 3Completed
- Sponsor
- Soligenix
- Start
- Dec 2017
- Primary completion
- Jun 2020
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Peptides
- Countries
- 5
01
Overview
A Phase 3 trial of dusquetide in oral mucositis (OM), sponsored by Soligenix. Started Dec 2017; status: completed.
02
Drugs
dusquetide
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT03237325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237325.